Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus

Xiaofeng ZHANG; Jinjun CHEN

doi:10.3969/j.issn.1001-5256.2022.06.001

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1217-1219

PDF( 1911 KB)

Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus

DOI: 10.3969/j.issn.1001-5256.2022.06.001

Xiaofeng ZHANG^{1, 2},
Jinjun CHEN^{1, 2, 3
,
,
,}

1.
Hepatology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2.
Department of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Guangzhou 511300, China
3.
Hepatology Institute of Guangdong Province, Guangzhou 510515, China

More Information

Corresponding author: CHEN Jinjun, chjj@smu.edu.cn (ORCID: 0000-0003-4275-9149)
Received Date: 2022-05-06
Accepted Date: 2022-06-06
Published Date: 2022-06-20

Abstract

Abstract

The new consensus on portal hypertension issued by Baveno Cooperative Group, i.e., the Baveno Ⅶ consensus, summarizes the diagnostic criteria for portal hypertension, noninvasive screening and diagnosis, primary prevention including etiological treatment and non-etiological treatment, secondary prevention including endoscopy and vascular intervention for diagnosis and treatment, new concepts associated with decompensated liver cirrhosis, and major advances and research agenda for the research directions including liver vascular diseases. Baveno Ⅶ consensus has an important reference value for clinical practice and research in the related fields of portal hypertension in China. As a part of the special issue, this article briefly describes the advances and challenges in portal hypertension in China from the perspective of clinical practice.
- Liver Cirrhosis,
- Portal Hypertension,
- Baveno Ⅶ Consensus

FullText(HTML)

References(20)

References

[1]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[2]	ZHANG XF, HE QJ, CHEN JJ. An excerpt of Report of the Baveno Ⅶ Consensus Workshop: Personalized care in portal hypertension[J]. J Clin Hepatol, 2022, 38(6): 1258-1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010. 张晓丰, 何钦俊, 陈金军. 《Baveno Ⅶ门静脉高压共识更新: 门静脉高压的个体化管理》摘译[J]. 临床肝胆病杂志, 2022, 38(6) 1258-1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010.
[3]	FERRUSQUÍA-ACOSTA J, BASSEGODA O, TURCO L, et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis[J]. J Hepatol, 2021, 74(4): 811-818. DOI: 10.1016/j.jhep.2020.10.003.
[4]	ZHANG W, PENG C, ZHANG S, et al. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension[J]. Gastrointest Endosc, 2021, 93(3): 565-572. DOI: 10.1016/j.gie.2020.06.065.
[5]	ZHOU YJ, GAO F, LIU WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno Ⅵ elastography cutoffs in Asian patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2021, 54(4): 470-480. DOI: 10.1111/apt.16487.
[6]	JI Y, LI J, HE Q, et al. Baveno Ⅵ elastography criteria for ruling in cACLD works well in patients with MAFLD[J]. J Hepatol, 2021, 75(5): 1243-1245. DOI: 10.1016/j.jhep.2021.06.003.
[7]	WANG H, WEN B, CHANG X, et al. Baveno Ⅵ criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis[J]. J Hepatol, 2021, 74(3): 584-592. DOI: 10.1016/j.jhep.2020.09.034.
[8]	YAN Y, LI Y, FAN C, et al. A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients[J]. Hepatol Int, 2022, 16(2): 423-432. DOI: 10.1007/s12072-021-10292-6.
[9]	LIU Y, NING Z, ÖRMECI N, et al. Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2998-3007. e5. DOI: 10.1016/j.cgh.2020.03.034.
[10]	QI X, AN W, LIU F, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology, 2019, 290(2): 370-377. DOI: 10.1148/radiol.2018180425.
[11]	SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
[12]	LV Y, ZUO L, ZHU X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study[J]. Gut, 2019, 68(7): 1297-1310. DOI: 10.1136/gutjnl-2018-317057.
[13]	LUO X, XIANG T, WU J, et al. Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial[J]. Hepatology, 2021, 74(4): 2074-2084. DOI: 10.1002/hep.31718.
[14]	LV Y, CHEN H, LUO B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial[J]. Hepatology, 2022. DOI: 10.1002/hep.32453.[Online ahead of print]
[15]	ZHANG Y, XU BY, WANG XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2564-2572. e1. DOI: 10.1016/j.cgh.2020.02.037.
[16]	LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.
[17]	LV Y, HE C, WANG Z, et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis[J]. Radiology, 2017, 285(3): 999-1010. DOI: 10.1148/radiol.2017162266.
[18]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Dig Dis, 2021, 22(4): 176-186. DOI: 10.1111/1751-2980.12970.
[19]	HE ZY, WANG BQ, YOU H. Reversal of cirrhotic decompensation: re-compensation[J]. Chin J Hepatol, 2019, 27(12): 915-916. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002. 何志颖, 王冰琼, 尤红. 肝硬化失代偿的逆转: 再代偿[J]. 中华肝脏病杂志, 2019, 27(12): 915-916. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.002.
[20]	ZHUGE YZ, WANG Y, ZHANG F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease[J]. Liver Int, 2018, 38(10): 1867-1874. DOI: 10.1111/liv.13684.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (874) PDF downloads(276)

Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus

DOI: 10.3969/j.issn.1001-5256.2022.06.001

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus

DOI: 10.3969/j.issn.1001-5256.2022.06.001

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content